British Journal of Haematology

Papers
(The H4-Index of British Journal of Haematology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Issue Information129
e‐Posters94
Don't forget cord blood in non‐remission acute myeloid leukaemia!88
Issue Information81
Immunophenotypic clustering in paediatric acute myeloid leukaemia66
Issue Information59
56
Quality of life in childhood immune thrombocytopenia: Revision of the Kids' ITP Tools (KIT)54
Would you like to take some more ruxolitinib after your fedratinib?54
Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L‐ASP: A retrospective analysis with an ASP‐based protocol in adult patients with acute lympho50
Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant48
Obinutuzumab as consolidation after chemo‐immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial47
Unveiling the responsible antigen in vaccine‐induced immune thrombotic thrombocytopenia47
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia47
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells45
Concomitant HIV‐associated plasmablastic lymphoma and visceral leishmaniasis at initial presentation44
44
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation43
Clinical outcomes and safety in patients with lower‐risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial43
Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore)42
A novel PML germline variant as a candidate predisposing genetic aberration in familial acute myeloid leukaemia42
Correction to “Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML 41
Haematopoietic stem cell mobilisation followed by high‐dose chemotherapy and autologous stem cell transplantation for patients with sickle cell disease and myeloma38
Evaluating the impact of thrombopoietin receptor agonist medications on patient outcomes and quality of life in paediatric immune thrombocytopenia through semi‐structured interviews36
ATG versus PTCy in matched unrelated donor haematopoietic stem cell transplantations with non‐myeloablative conditioning36
R‐CHOP treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of JCOG020336
Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic cell transplant: Feasibility, anti‐leukaemic potential and alloreactivity across major human leukoc35
No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry35
Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)35
CAR T in patients with large B‐cell lymphoma not fit for autologous transplant35
MYC‐induced cytidine metabolism regulates survival and drug resistance via cGas‐STING pathway in mantle cell lymphoma35
Antibody response to a third SARS‐CoV‐2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation34
Indirect presentation of mismatched human leukocyte antigen ‐B associates with outcomes of cord blood transplantation32
1.4117829799652